 has released updated guidelines to help doctors treat patients with locally advanced rectal cancer){kind=link}
The American Society of Clinical Oncology (ASCO) has released updated guidelines to help doctors treat patients with locally advanced rectal cancer. These guidelines are built on a thorough review of research from the past decade, aiming to provide clear, evidence-based recommendations while acknowledging the complexity of each patient’s situation.
A key takeaway from the new guidelines is the emphasis on personalized treatment. For patients with specific types of tumors, ASCO recommends starting with a combination of chemoradiation and chemotherapy, especially for those with tumors in the lower rectum or at a higher risk of spreading. For others, there are more options, including different combinations of chemotherapy and radiation, depending on how the tumor responds.
One notable aspect of the guidelines is the option for nonoperative management. For patients whose tumors respond exceptionally well to initial treatments, surgery might not be the only route, other less invasive options could be considered.
Additionally, the guidelines recommend immunotherapy for patients with certain genetic tumor profiles, providing an alternative to traditional treatments.
These guidelines aren’t a one-size-fits-all solution but are meant to guide discussions between doctors and patients, helping to tailor treatment plans that best fit each individual’s needs. As ASCO highlights, every patient’s situation is unique, and these guidelines are there to support, not replace, a doctor’s judgment.